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Background: L-2-hydroxyglutaric aciduria is a metabolic repair deficiency characterized by elevated levels of
L-2-hydroxyglutaric acid in urine, blood and cerebrospinal fluid. Neurological signs associated with the disease in
humans and dogs include seizures, ataxia and dementia.
Case presentation: Here we describe an 8 month old Yorkshire terrier that presented with episodes of
hyperactivity and aggressive behavior. Between episodes, the dog’s behavior and neurologic examinations were
normal. A T2 weighted MRI of the brain showed diffuse grey matter hyperintensity and a urine metabolite screen
showed elevated 2-hydroxyglutaric acid. We sequenced all 10 exons and intron-exon borders of L2HGDH from the
affected dog and identified a homozygous A to G transition in the initiator methionine codon. The first inframe
methionine is at p.M183 which is past the mitochondrial targeting domain of the protein. Initiation of translation at
p.M183 would encode an N-terminal truncated protein unlikely to be functional.
Conclusions: We have identified a mutation in the initiation codon of L2HGDH that is likely to result in a non-
functional gene. The Yorkshire terrier could serve as an animal model to understand the pathogenesis of
L-2-hydroxyglutaric aciduria and to evaluate potential therapies.
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L-2 hydroxyglutaric aciduria (L-2-HGA) was first
described in 1980 in a young boy with psychomotor re-
tardation and musculoskeletal dystrophy [1]. This rare
autosomal recessive inherited disease is characterized by
an elevated concentration of L-2-hydroxyglutaric acid in
plasma, cerebrospinal fluid, and urine [1]. In human
patients, the clinical features are mild psychomotor
delay, followed by progressive cerebellar ataxia, dysarth-
ria, moderate to severe mental deterioration and in some
cases seizures [2,3]. Magnetic resonance imaging (MRI)
of L-2-HGA patients shows abnormal signal in the per-
ipheral subcortical white matter, basal ganglia and den-
tate nuclei. Also, cerebellar atrophy is present. The* Correspondence: fhfdpd@mail.missouri.edu
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reproduction in any medium, provided the ordistribution of signal abnormalities in the MRI of L-2-
HGA patients is distinct and differentiates it from other
diseases [4,5].
In 2004, mutations in L2HGDH were shown to cause
human L-2-HGA [3,6]. L2HGDH is comprised of 10
exons which encode a protein of 463 amino acids that
contains a N-terminal mitochondrial targeting sequence
and C-terminal amino acid sequence homology to FAD-
dependent oxidoreductases [6]. L-2-hydroxyglutarate de-
hydrogenase is bound to mitochondrial membranes and
catalyzes the conversion of L-2-hydroxyglutarate to α-
ketoglutarate [6].
L-2-HGA was described in Staffordshire bull terriers
in 2003 [7]. These dogs presented with ataxia, dementia,
tremors and seizures, and they showed MRI changes
similar to the human disease. L-2-hydroxyglutaric acid
levels were elevated in urine, cerebrospinal fluid and
plasma from affected dogs. In 2007, Penderis et al. [8]td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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predicting a two amino acid substitution in Staffordshire
bull terriers affected with L-2-HGA. A case of L-2-HGA
was also reported in a West Highland white terrier with
clinical and MRI characteristics of the disease [9], but no
molecular genetic cause was determined. In this report,
we describe the clinical features and the likely molecular
genetic cause of L-2-HGA in a Yorkshire terrier.
Case presentation
An 8 month old neutered male Yorkshire terrier was
presented with episodes of hyperactivity and aggres-
sive behavior. The episodes would last for about 40
minutes and then the dog behaved normally between
episodes. No abnormalities were found on neurologic
examination. Cerebrospinal fluid analysis showed a
mild mononuclear pleocytosis (WBC 23/ul {N<8}
with 92% mononuclear cells and 8% small lympho-
cytes) and normal protein (7 mg/dl {N<36}). An
MRI of the brain (Figure 1) demonstrated hyperin-
tensity of the gray matter of the thalamus, cerebral
cortex and cerebellum on T2 weighted images simi-
lar to previously described MRIs from Staffordshire
bull terriers and a West Highland white terrier with
L-2-HGA [7,9]. No abnormalities were apparent on
FLAIR, gradient echo or T1 weighted images with or
without gadolinium contrast. Urine organic acid
levels were quantified by gas chromatography-massFigure 1 Transverse T2-weighted image (TR= 3000, TE= 90)
through the midbrain of the Yorkshire terrier with L-2-HGA. The
gray matter of the cerebrum and brainstem shows the symmetric
hyperintensity characteristic of the disease [7,9].spectroscopy as previously described [10], and showed
an elevated concentration of hydroxyglutaric acid
(1,743 mmol/mol creatinine {N = 0.6–5.7}). Plasma
amino acid levels were also quantified and showed ele-
vated lysine (600 μmol/L {N = 145–201}). A lysine
restricted diet was developed, but it was not palatable
so the dog was placed on a commercial protein
restricted diet1. The dog was also started on phenobarbital
at 2.5 mg/kg. The frequency of the episodes decreased
with treatment, and the dog showed no progression of
signs over 6 months.
Because MRI findings and urinary organic acid pro-
files were consistent with a diagnosis of L-2-HGA,
L2HGDH became the most likely candidate gene to
harbor the mutation responsible for the 2-HGA in
this dog. DNA was extracted from an EDTA blood
sample using a previously described method [11].
First, we eliminated the presence of the mutation
identified in Staffordshire bull terriers [8]. To investi-
gate whether there were other sequence variants in
the affected dog’s L2HGDH, we sequenced all 10
exons and intron–exon junctions as previously
described [12]. Primer sequences are provided in
Additional file 1. Comparison of the sequencing data
from all 10 exons of canine L2HGDH from the
affected dog to the published canine sequence
(Ensembl Gene ID ENSCAFG0000001437) revealed a
homozygous c.1A>G substitution (Figure 2). This nu-
cleotide substitution changes the initiation methionine
codon, which is predicted to alter the translation start
site [13].
We genotyped 6 unaffected Yorkshire terriers and 97
dogs from other breeds at L2HGDH:c.1 by PCR-RFLP
with PCR primers 5′-GCGCTCGATTGGCCCTTG-3′
and 5′-GCAGGCCAGCGGCTACTCAC-3′ which pro-
duced a 298 bp amplicon. The wild type allele was
hydrolyzed by restriction enzyme NcoI into fragments of
157 and 141 bp; whereas, the mutant allele lacked the
NcoI restriction site. All 103 normal dogs were homozy-
gous for the wild type A allele.
L2HGDH encodes a FAD-dependent L-2-hydroxy-
glutarate dehydrogenase that is bound to mitochon-
drial membranes and converts L-2-hydroxyglutarate
to α-ketoglutarate [6]. L-2-hydroxyglutarate is endogen-
ously produced but is not an intermediate of any currently
recognized mammalian metabolic pathway. Instead, L-2-
hydroxyglutarate is formed because mitochondrial L-malate
dehydrogenase is not completely specific for oxaloacetate,
its primary substrate. This enzyme can also reduce α-
ketoglutarate to L-2-hydroxyglutarate as a side reaction
[14]. L-2-hydroxyglutarate dehydrogenase prevents the ac-
cumulation of L-2-hydroxyglutarate by FAD-dependent
oxidation back to α-ketoglutarate. Thus, L-2-HGA is con-
sidered to be a deficiency of ‘metabolite repair’ [6,15,16].
Figure 2 Partial nucleotide sequence of L2HGDH exon 1 from a control dog and the Yorkshire terrier with L-2-HGA illustrating the
L2HGDH:c.1A>G mutation.
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dehydrogenase deficiency is the accumulation of L-2-
hydroxyglutarate. L-2-hydroxyglutarate induces oxidative
stress and inhibits mitochondrial creatine kinase in the
cerebellum [17,18]. Also, L-2-hydroxyglutarate is a struc-
tural analog of glutamate, and thus a potential inhibitor
of the many biologic processes that involve this key me-
tabolite and neurotransmitter [15]. The exact mechan-
ism by which accumulation of L-2-hydroxyglutaric acid
causes brain injury is still unknown.
Since the identification of the first human L2HGDH
mutations [3,6], about 70 L-2-HGA-causing mutations
have been reported [19]. Among these are two that
occur in the initiator codon (c.1A>C and c.1A>G), simi-
lar to the canine L2HGDH:c.1A>G mutation reported
here. The canine initiator codon mutation was absent
from 103 unaffected dogs. Mutations in initiator codons
require the use of an alternative downstream methionine
codon [13]. The next potential translational start site in
the canine L2HGDH is out of frame and would encode a
peptide of only 4 amino acids before it reaches a stop
codon. The first inframe methionine codon is located
183 codons downstream from the original start codon,
which if used would encode a protein without the N-
terminal mitochondrial targeting domain [15]. Thus, the
mutant L2HGDH in the Yorkshire terrier with L-2-HGA
is unlikely to be functional.
The only clinical signs shown by the Yorkshire terrier
were episodes of hyperactivity and aggression. At the
time of this report, the dog has not shown any dementia,
ataxia or generalized seizures as has been described in
human patients and dogs with L-2-HGA from other
breeds. Unless there is an unidentified splice variant that
provides an alternative initiator methionine codon, the
milder phenotype is unlikely to be due to residual en-
zyme activity. It could reflect a response to therapy or
the younger age of the Yorkshire terrier. The decreased
severity may have been due to the altered diet or to thephenobarbital therapy which would suggest that these
episodes were complex partial seizures, possibly with
post-ictal behavior changes.
Conclusion
We described a previously unreported mutation in
L2HGDH in a Yorkshire terrier with L-2-HGA. This mu-
tation is predicted to result in a non-functional gene. We
recently learned that another group has independently
found the same mutation in two European Yorkshire terri-
ers with L-2-HGA [20]. The occurrence of L-2-HGA in
two European Yorkshire terriers with an identical mutation
is additional evidence that the L2HGDH:c.1A>G transition
is the cause of L-2-HGA in this breed. The similarities be-
tween canine L-2-HGA and the human disease suggest that
the canine disease could be a useful model to understand
the pathogenesis of the disease and to evaluate potential
therapies.
Endnotes
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